Cargando...
Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
BACKGROUND: The regimen of concurrent administration of trastuzumab and anthracyclines in the adjuvant treatment of breast cancer has never been evaluated prospectively for fear of cardiac toxicity. METHODS: Patients with HER2-positive operable breast cancer were randomised to receive adjuvant treat...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5696221/ https://ncbi.nlm.nih.gov/pubmed/29190955 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21579 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|